{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:59:55Z","timestamp":1780981195693,"version":"3.54.1"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fabry disease, an X-linked lysosomal storage disorder, can present with mixed ventilatory dysfunction on pulmonary function testing. In patients with a smoking history, this finding may trigger a reflexive consideration of COPD and unnecessary bronchodilator use. We report a case where bronchodilators were briefly used following the diagnosis of Fabry disease, highlighting the clinical inertia that persists even after a definitive diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>\n                      A 39-year-old male with a 20-pack-year smoking history was diagnosed with Fabry disease through family cascade screening (\u03b1-galactosidase A activity: 4.93\u00a0nmol\/L; plasma lyso-Gb3: 328.92\u00a0nmol\/L; hemizygous GLA variant). Multisystem evaluation revealed mixed ventilatory dysfunction (FEV\n                      <jats:sub>1<\/jats:sub>\n                      \/FVC 54.59%) without respiratory symptoms, left ventricular hypertrophy (septum 14\u201317\u00a0mm, posterior wall 15\u00a0mm), proteinuria (1.01\u00a0g\/24\u00a0h), and corneal verticillata. Chest CT showed no emphysema. During hospitalization, inhaled budesonide plus ipratropium bromide (a bronchodilator) was briefly administered. However, recognizing that the ventilatory dysfunction was a manifestation of Fabry disease itself rather than COPD, the patient was discharged without a bronchodilator prescription. Enzyme replacement therapy (ERT) with agalsidase alfa (0.2\u00a0mg\/kg every 2\u00a0weeks) was initiated as long-term disease-modifying treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Even after Fabry disease is confirmed, the presence of a smoking history and abnormal spirometry can trigger reflexive bronchodilator use, illustrating powerful clinical inertia. Respiratory physicians should strictly adhere to COPD diagnostic criteria. Once Fabry disease is diagnosed, ERT should be prioritized as the disease-modifying therapy, and bronchodilators, if used at all, should be reserved for symptomatic patients as an adjunct, not a substitute.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1843864","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:33:06Z","timestamp":1780979586000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Is it COPD? It is Fabry disease: a case in which bronchodilators were briefly used but not continued, prioritizing enzyme replacement therapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Yanyan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The Affiliated Changde Hospital of Xiangya School of Medicine, Central South University","place":["Changde, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyi","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Science and Education Section, The Affiliated Changde Hospital of Xiangya School of Medicine, Central South University","place":["Changde, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijie","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Affiliated Changde Hospital of Xiangya School of Medicine, Central South University","place":["Changde, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Quality Control, The Affiliated Changde Hospital of Xiangya School of Medicine, Central South University","place":["Changde, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Affiliated Changde Hospital of Xiangya School of Medicine, Central South University","place":["Changde, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhui","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Affiliated Changde Hospital of Xiangya School of Medicine, Central South University","place":["Changde, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Affiliated Changde Hospital of Xiangya School of Medicine, Central South University","place":["Changde, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Affiliated Changde Hospital of Xiangya School of Medicine, Central South University","place":["Changde, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Affiliated Changde Hospital of Xiangya School of Medicine, Central South University","place":["Changde, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"14799731231221821","DOI":"10.1177\/14799731231221821","article-title":"Respiratory impairments in patients suffering from fabry disease-across-sectional study","volume":"21","author":"Ahmed","year":"2024","journal-title":"Chron. Respir. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical fabry disease:a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.3390\/ijms25084299","article-title":"Phenotypic expression and outcomes in patients with the p. Arg301Gln GLA variant in anderson-fabry disease","volume":"25","author":"Blanco","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1164\/ajrccm.155.3.9116979","article-title":"Pulmonary involvement in Fabry disease","volume":"155","author":"Brown","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1164\/rccm.202204-0671PP","article-title":"Definition and nomenclature of chronic obstructive pulmonary disease: time for ItsRevision","volume":"206","author":"Celli","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3760\/cma.j.cn112148-20231008-00263","article-title":"Expert consensus on the diagnosis and treatment of adult Fabry disease cardiomyopathy","volume":"53","year":"2024","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"B8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.ejim.2013.05.003","article-title":"Pulmonary involvement in Fabry disease: overview and perspectives","volume":"24","author":"Franzen","year":"2013","journal-title":"Eur. J. Intern Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J. Med. Genet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.1038\/s41598-023-31777-4","article-title":"Optimizing human \u03b1-galactosidase for treatment of Fabry disease","volume":"13","author":"Hallows","year":"2023","journal-title":"Sci. Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3238\/arztebl.2009.0440","article-title":"Fabry disease\u2014 often seen, rarely diagnosed","volume":"106","author":"Hoffmann","year":"2009","journal-title":"Dtsch. Arztebl Int."},{"key":"B13","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1007\/s10545-007-0616-9","article-title":"Natural history of the respiratory involvement in Anderson-Fabry disease","volume":"30","author":"Magage","year":"2007","journal-title":"J. Inherit Metab Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the FabryOutcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. Invest"},{"key":"B15","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"B16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pcad.2025.08.003","article-title":"Fabry disease cardiomyopathy: a state-of-the-art review","volume":"92","author":"Pande","year":"2025","journal-title":"Prog. Cardiovasc Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol. Dial. Transpl."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1843864\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:33:36Z","timestamp":1780979616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1843864\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":17,"alternative-id":["10.3389\/fphar.2026.1843864"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1843864","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"article-number":"1843864"}}